Renaissance Capital counted three biotechs among the mix of IPOs expected to price this week. They run the gamut from Ultragenyx, a 2013 Fierce 15 winner with a pipeline of experimental therapies for rare diseases, to Cara Therapeutics and Dicerna.

…read more

Source: Tsunami of biotech IPOs will test investors’ appetite for R&D


0 No comments